Considering changes in certain genetic alternations such as PTEN, p53, and KRAS have been shown to influence the sensitivity of cancer cells to onvansertib in preclinical models and some clinical trials, the identification of biomarkers that affect the sensitivity of EC to onvansertib in our subsequent studies is crucial to improve patient selection and enhance clinical treatment outcomes (Stebbing and Bullock, 2024b; Degenhardt et al., 2010). Here, TP53 is linked to cancer.